ES2070131T3 - Sistemas farmaco-lipido de baja toxicidad. - Google Patents

Sistemas farmaco-lipido de baja toxicidad.

Info

Publication number
ES2070131T3
ES2070131T3 ES88400520T ES88400520T ES2070131T3 ES 2070131 T3 ES2070131 T3 ES 2070131T3 ES 88400520 T ES88400520 T ES 88400520T ES 88400520 T ES88400520 T ES 88400520T ES 2070131 T3 ES2070131 T3 ES 2070131T3
Authority
ES
Spain
Prior art keywords
lipid
compositions
hdlcs
lipid complexes
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88400520T
Other languages
English (en)
Other versions
ES2070131T5 (es
Inventor
Lawrence Boni
Pieter R Cullis
Anthony G Durning
Andrew S Janoff
John J Kearns
Robert Klimchak
Robert P Lenk
Thomas Madden
Joel Portnoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27361805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2070131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of ES2070131T3 publication Critical patent/ES2070131T3/es
Application granted granted Critical
Publication of ES2070131T5 publication Critical patent/ES2070131T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B2227/00—Photographic printing apparatus
    • G03B2227/32—Projection printing apparatus, e.g. enlarging apparatus, copying camera
    • G03B2227/325—Microcapsule copiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Vehicle Step Arrangements And Article Storage (AREA)
  • Catalysts (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)

Abstract

SE DESCRIBEN METODOS Y COMPOSICIONES DE COMPLEJOS DE LIPIDOS NO LIPOSOMICOS EN ASOCIACION CON FARMACOS HIDROFOBOS TOXICOS TALES COMO EL ANTIBIOTICO POLIENICO ANFOTERICINA B. LAS COMPOSICIONES LIPIDICAS SON PREFERIBLEMENTE UNA COMBINACION DE LOS FOSFOLIPIDOS DIMIRISTOILFOSFATIDIL-COLINA (DMPC) Y DIMIRISTOILFOSFATIDILGLICERINA (DMPG) EN UNA PROPORCION MOLAR DE ALREDEDOR DE 7:3. LOS COMPLEJOS LIPIDICOS CONTIENEN UN AGENTE BIOACTIVO, YSE PUEDEN PREPARAR POR DIVERSOS PROCEDIMIENTOS A UNAS PROPORCIONES ALTAS DE FARMACO: LIPIDO. ESTAS COMPOSICIONES PUEDEN SER ADMINISTRADAS A MAMIFEROS INCLUYENDO AL HOMBRE, PARA EL TRATAMIENTO DE INFECCINES, CON EFICACIA EQUIVALENTE OMAYOR Y TOXICIDADES DEL FARMACO REDUCIDAS EN COMPARACION CON ESTE DE FORMA LIBRE. TAMBIEN INCLUYE LA INVENCION UN NUEVO PROCEDIMIENTO DE CARGA DE LIPOSOMA, QUE SE PUEDE EMPLEAR EN LA FORMACION DE LAS COMPOSICIONES CONALTA PROPORCION DE FARMACO Y LIPIDO.
ES88400520T 1987-03-05 1988-03-04 Sistemas de farmaco-lipido de baja toxicidad. Expired - Lifetime ES2070131T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2215787A 1987-03-05 1987-03-05
US6990887A 1987-07-06 1987-07-06
US7930987A 1987-07-29 1987-07-29

Publications (2)

Publication Number Publication Date
ES2070131T3 true ES2070131T3 (es) 1995-06-01
ES2070131T5 ES2070131T5 (es) 1998-10-01

Family

ID=27361805

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88400520T Expired - Lifetime ES2070131T5 (es) 1987-03-05 1988-03-04 Sistemas de farmaco-lipido de baja toxicidad.

Country Status (20)

Country Link
EP (1) EP0282405B2 (es)
KR (1) KR970002870B1 (es)
CN (1) CN1044093C (es)
AT (1) ATE118169T1 (es)
AU (1) AU622405B2 (es)
CA (1) CA1338701C (es)
DE (1) DE3852961T3 (es)
DK (1) DK176010B1 (es)
ES (1) ES2070131T5 (es)
FI (1) FI102724B1 (es)
GR (1) GR3015916T3 (es)
HK (1) HK1007495A1 (es)
IE (1) IE67152B1 (es)
IL (1) IL85607A (es)
LU (1) LU88684I2 (es)
NL (1) NL990004I1 (es)
NO (4) NO179995C (es)
NZ (1) NZ223660A (es)
PT (1) PT86913B (es)
WO (1) WO1988006443A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US5830498A (en) * 1987-10-16 1998-11-03 Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
CA2050679C (en) * 1989-03-31 1998-09-22 Francis C. Szoka, Jr. Preparation of liposome and lipid complex compositions
US5188951A (en) * 1990-04-17 1993-02-23 The Liposome Company, Inc. Enzymatic synthesis of soluble phosphatides from phospholipids
DE4108903A1 (de) * 1990-08-06 1992-02-13 Nattermann A & Cie Pharmazeutisches produkt
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
US5534502A (en) * 1990-11-06 1996-07-09 Nippon Shinyaku Co. Ltd. Process for producing fat emulsion
WO1992007571A1 (fr) * 1990-11-06 1992-05-14 Nippon Shinyaku Co., Ltd. Procede de production d'une emulsion grasse
EP0599977A1 (en) * 1991-08-14 1994-06-08 SEQUUS PHARMACEUTICALS, INC. (a Delaware Corporation) Hiv-treatment method with low-toxicity amphotericin b
JPH08510748A (ja) * 1993-05-21 1996-11-12 ザ リポソーム カンパニー、インコーポレーテッド リポソームが誘発する生理的副作用の低減
US5716526A (en) * 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
WO2007067784A2 (en) * 2005-12-08 2007-06-14 Wyeth Liposomal compositions
KR101132626B1 (ko) * 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
AU2010359346B2 (en) 2010-08-20 2015-01-29 Dr. Reddy's Laboratories Sa Phospholipid depot
ES2640756T3 (es) 2010-10-22 2017-11-06 Dr. Reddy's Laboratories Sa. Uso de depósitos de fosfolipidos viscosos estables para tratar heridas
RU2678433C2 (ru) 2012-05-10 2019-01-29 Пейнреформ Лтд. Депо-составы гидрофобного активного ингредиента и способы их получения
WO2016205384A1 (en) 2015-06-15 2016-12-22 The University Of Washington Multiple drug lipid nanoparticle composition and related methods for extended drug levels in blood and lymph tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4436746A (en) * 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
IL78929A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration

Also Published As

Publication number Publication date
NO1998012I1 (no) 1998-03-25
KR970002870B1 (ko) 1997-03-12
DK176010B1 (da) 2005-11-28
ES2070131T5 (es) 1998-10-01
NO944071D0 (no) 1994-10-26
DK98089D0 (da) 1989-03-01
DE3852961D1 (de) 1995-03-23
NO1998013I1 (no) 1998-03-25
NO884391L (no) 1988-11-24
CN1044093C (zh) 1999-07-14
EP0282405A3 (en) 1989-01-04
DE3852961T2 (de) 1995-07-06
EP0282405B1 (en) 1995-02-08
CA1338701C (en) 1996-11-12
DK98089A (da) 1989-03-01
NZ223660A (en) 1990-11-27
EP0282405A2 (en) 1988-09-14
AU622405B2 (en) 1992-04-09
IL85607A0 (en) 1988-08-31
FI102724B (fi) 1999-02-15
IE67152B1 (en) 1996-03-06
GR3015916T3 (en) 1995-07-31
KR890700341A (ko) 1989-04-24
LU88684I2 (fr) 1996-04-29
NO180147C (no) 1997-02-26
HK1007495A1 (en) 1999-04-16
EP0282405B2 (en) 1998-07-22
NO180147B (no) 1996-11-18
PT86913B (pt) 1993-07-30
WO1988006443A1 (en) 1988-09-07
NO944071L (no) 1988-11-24
DE3852961T3 (de) 1998-12-24
FI102724B1 (fi) 1999-02-15
NO884391D0 (no) 1988-10-04
PT86913A (pt) 1989-03-30
NL990004I1 (nl) 1999-04-01
CN88101864A (zh) 1988-09-28
FI894161A0 (fi) 1989-09-04
ATE118169T1 (de) 1995-02-15
IE880600L (en) 1988-09-05
IL85607A (en) 1992-08-18
AU1799088A (en) 1988-09-26
NO179995B (no) 1996-10-21
NO179995C (no) 1997-01-29

Similar Documents

Publication Publication Date Title
ES2070131T3 (es) Sistemas farmaco-lipido de baja toxicidad.
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
ES2084041T3 (es) Composiciones antihipertensivas y uso de las mismas.
SE8504967L (sv) Farmaceutisk komposition och forfarande for behandling av kroppen
BG101118A (en) Therapeutical compounds
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ES2044843T3 (es) Uso de antibioticos de quinolona y naftiridina en la preparacion de medicamentos oftalmicos.
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
AU8687391A (en) Lithium treatment
ES2123004T3 (es) Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
DE3175733D1 (en) An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.
ES2061593T3 (es) Medicamento,2-isoxazolinas e isoxazoles con contenido de fosforo contenidos en el, asi como procedimiento de preparacion para estos compuestos heterociclicos.
IT1247093B (it) Derivati salini del gliceril fosforil mioinositolo ad attivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
MX9401370A (es) Terapia antiviral.
ITMI930273A0 (it) Composti terapeuticamente attivi, utili per il trattamento di malattie connesse con alterata funzionalita' del sistema immunitario procedimento per la loro preparazione e composizione farmaceutiche che li contengono
CA2080040A1 (en) Methods for preventing mycobacterial infections by administration of rifabutin
IT1251993B (it) Composizioni farmaceutiche ad uso orale,a base di esteri di gangliosidi,per il trattamento di neuropatie del sistema nervoso periferico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 282405

Country of ref document: ES